Summit Therapeutics Inc.SMMTNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-36.98%
↓ 311% below average
Average (39q)
17.56%
Historical baseline
Range
High:305.78%
Low:-68.41%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -36.98% |
| Q2 2025 | 305.78% |
| Q1 2025 | -0.26% |
| Q4 2024 | 36.25% |
| Q3 2024 | 22.49% |
| Q2 2024 | -0.24% |
| Q1 2024 | 58.61% |
| Q4 2023 | 27.03% |
| Q3 2023 | 62.13% |
| Q2 2023 | -4.37% |
| Q1 2023 | 83.49% |
| Q4 2022 | -68.41% |
| Q3 2022 | 89.27% |
| Q2 2022 | -56.18% |
| Q1 2022 | -11.04% |
| Q4 2021 | 15.87% |
| Q3 2021 | 15.31% |
| Q2 2021 | 17.65% |
| Q1 2021 | 53.88% |
| Q4 2020 | -10.20% |
| Q3 2020 | -7.34% |
| Q2 2020 | -22.88% |
| Q1 2020 | 81.88% |
| Q4 2019 | -12.17% |
| Q4 2019 | -16.85% |
| Q3 2019 | 4.76% |
| Q2 2019 | -14.50% |
| Q1 2019 | 20.13% |
| Q4 2018 | -19.53% |
| Q3 2018 | -18.44% |
| Q2 2018 | 13.22% |
| Q1 2018 | 42.89% |
| Q4 2017 | 12.94% |
| Q3 2017 | 33.41% |
| Q2 2017 | 1.80% |
| Q1 2017 | 32.43% |
| Q4 2016 | -32.30% |
| Q3 2016 | 1.57% |
| Q2 2016 | -1.32% |
| Q1 2016 | 2.46% |